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n66), 121 for Everolimus (E; n468), 143 for Sunitinib (Su; n1520) and 192 for
BevacizumabInterferon (B, n171). Approximately one quarter of patients were
lost in the second month of treatment (T39%; So36%, P35%; E28%; Su25%;
B21%). CONCLUSIONS: Persistence in first line treatment of mRCC is very low.
Best persistence can be observed for BevacizumabInterferon which is the only
intravenous treatment in this indication. Further research may be required to eval-
uate if the increased use of oral treatments has a negative impact on patient ad-
herence and if adequate measures are required to improve this situation.
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OBJECTIVES: Although ovarian cancer has been widely studied, there is very little
documentation of patient reported outcomes (PRO) for patients with platinum-
sensitive ovarian cancer (PSOC). Initial therapy for ovarian cancer typically consists
of surgery followed by platinum-based chemotherapy. Patients are considered
platinum-sensitive if disease recurrence occurs more than 6 months after comple-
tion of platinum-based treatment. The objective of this literature review was to
obtain a clear picture of patient reported outcomes (PROs) including health related
quality of life (HRQoL), patient preferences, and health status utility for patients
with PSOC. METHODS: A systematic literature review of the peer-reviewed litera-
ture was conducted in Medline and Embase using the Cochrane approach. Studies
reporting and analyzing PROs, HRQoL, patient preferences, and health status utility
in patients with PSOC over the past 10 years were identified. RESULTS: The review
identified 19 studies reporting PROs for PSOC patients, of which 9 were PSOC only,
7 were a combination of platinum-sensitive and resistant patients and 3 were
platinum-treated recurrent patients. Of these 19 studies, there was a wide varia-
tion, with limited commonality, on the types of treatment regimens reported. In
general, QoL did not differ between therapies for PSOC patients. However, in one
study when docetaxel and carboplatin were given sequentially vs. in combination,
an improvement in QoL was demonstrated. Another study showed that statisti-
cally significant higher QoL scores were found in pegylated liposomal doxorubicin
treated patients than in gemcitabine patients. CONCLUSIONS: Given the limited
number of PSOC references and variations in treatment regimens, it was difficult to
identify common themes in patient preferences and PROs for this patient popula-
tion. PSOC patients’ preferences and perceptions of treatment are important; how-
ever, this information is missing in the evidence base. Further research is needed to
identify treatment options which improve QoL and add value to PSOC patients’
treatment experience.
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OBJECTIVES: Chronic Myeloid Leukemia (CML) is a hematologic, mostly fatal can-
cer. With the introduction of the targeted therapy imatinib, life expectancy for
these patients dramatically increased (Garcia-Manero, 2003, Deininger, 2008).
Therefore, the assessment of quality of life (QoL) is increasingly important to CML
patients taking a lifelong medication. The aim of our cross-sectional pilot study
was to assess CML patient QoL using the Euro Quality of Life-5 Dimensions (EQ-5D)
and derive utility values for each patient. METHODS: Patients with CML in Inns-
bruck, Austria completed the EQ-5D either on a tablet PC or via postal survey.
According to the ethic committee vote, inclusion criteria were: prior diagnosis of
CML, fluency in the German language, age between 18 and 80 years, and expected
survival time of at least three months. The analysis included descriptive statistics
of the sample and derivation of a utility value for each patient. RESULTS:Out of the
47 questionnaires that were sent out via mail, 31 were returned. An additional 4
patients filled out the EQ-5D using a tablet PC. Nine patients were excluded due to
lack of clinical data and/or failure to complete the questionnaire. Of the 26 patients
in the final sample, 21 patients (81%) were in the chronic phase of disease and five
(19%) had undergone allogeneic stem cell transplantation (SCT). Patients who had
undergone a SCT had a median utility of 0.701 (range 0.197-1.0); patients in the
chronic phase had a median utility of 0.887 (range 0.262-1.0).The difference be-
tween these two groups was not statistically significant (p0.345). CONCLUSIONS:
Due to limited sample size, our results should be interpreted with caution. It is
important for clinicians and health policy decision makers to consider mortality
reduction, but also consider the patients’ QoL and patient preferences in a stan-
dardized and systematic way to optimize patient care.
PCN110
DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN CHILDREN
TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) ON DANA FARBER
CANCER INSTITUTE (DFCI) PROTOCOLS
Rae CS1, Horsman JR2, Furlong W2, Silverman LB3, Sallan SE3, Athale U1, Pullenayegum
E1, Barr RD1
1McMaster University, Hamilton, ON, Canada, 2Health Utilities Inc., Dundas, ON, Canada,
3Harvard Medical School, Boston, MA, USA
OBJECTIVES: To identify differences in health-related quality of life (HRQL) be-
tween 2 consecutive Dana Farber Cancer Institute (DFCI) protocols to treat acute
lymphoblastic leukemia (ALL) diagnosed during childhood. METHODS: Children
diagnosed with standard and high risk ALL and treated according to DFCI protocol
95-001 or 00-001 at 5 and 9 Centres, respectively, in Canada and the USA were
eligible for study. Parents of patients completed Health Utilities Index (HUI) ques-
tionnaire assessments during each of 4 major phases of therapy (induction of
remission, central nervous system-directed treatment, intensification, continua-
tion), and at 2 years post-treatment. Differences between protocols in mean HRQL
scores for each phase were assessed using a t-test for independent groups. Quality-
adjusted life years (QALYs), based on mean HRQL scores for and duration of each
protocol phase, were used to determine the importance of differences. RESULTS:A
total of 381 (00-001) and 375 (95-001) patients were assessed. There were no differ-
ences between protocols in the distribution of patients by gender (p0.66) or risk
group (p0.56). During the first phase of treatment, the mean HRQL score of 00-01
patients (0.75) was importantly better (diff0.18, p0.03) than 95-001 patients
(0.67). Differences during this phase were in the attributes of dexterity (p0.03) and
emotion (p0.009). There were no significant differences (p0.05) between groups
during any of the other phases or post-treatment. Over the 5 year period, 00-001
patients experienced 0.06 greater QALYs, or 3 quality-adjusted life weeks (QALW),
than 95-001 patients. CONCLUSIONS: Assuming similar or reduced relapse and
mortality rates, 3 QALW represents an important gain in HRQL for the more recent
DFCI 00-01 protocol.
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OBJECTIVES: The benefit of adjuvant chemotherapy for early-stage breast cancer
(BrCa) patients depends on baseline recurrence risk. Gene expression profiling
(GEP) of tumours informs baseline risk prediction, potentially reducing unneces-
sary treatment and health care costs. Limited evidence exists on its clinical utility;
we explored patients’ and oncologists’ perspectives on GEP in chemotherapy
decisions. METHODS: We conducted individual interviews with medical oncolo-
gists (n10), plus focus groups and individual interviews with BrCa patients (n20)
from Ontario, Canada. BrCa patients who underwent genomic testing (‘On-
cotypeDx’), were recruited through oncology clinics from two academic hospitals
in the Greater Toronto Area. Medical oncologists were recruited through partici-
pating oncology clinics, professional advertisements and referrals from the re-
search team. Data were analyzed using interpretative qualitative methods, includ-
ing content analysis, qualitative description and constant comparison techniques.
RESULTS: Patients and oncologists valued GEP as an additional decision-support
tool, complementing existing clinical indicators, though perceived utility varied
between patients and oncologists. Patients valued the test highly, suggesting it was
one of the primary determinants of their treatment decision. All patients followed
the course of action their results suggested. Patients with intermediate scores often
used the results to reinforce their pre-existing treatment preferences. Oncologists
were mixed about the test’s utility. Some considered it another tool supporting
their approach to risk assessments; others used it more definitively to resolve their
uncertainty. Oncologists explained the test’s contribution to decision-making but
remained uncertain about patients’ understanding and expectations of the test.
Some raised concerns about the variability of its use and interpretation within their
medical community. CONCLUSIONS: Patients and oncologists valued the test, of-
ten using it as a primary determinant in their treatment decision, despite oncolo-
gists’ concerns about its technical limitations and patients’ limited understanding.
Results identify need for informational decision aids and practice guidelines to
support patient understanding and standardized application of the test.
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OBJECTIVES: Cytotoxic chemotherapy has been the main approaches to cancer
therapy, but frequently poor survival benefit and substantial toxicity is observed.
Over the past decade, cytostatic drugs has been developed and hoped that such
anticancer agents would have low toxicity and prolong survival. In Korea, cytotoxic
therapy is also the standard of cancer treatments, and the National Health Insur-
ance (NHI) program pays 95% of the total medical cost for cancer patients. However,
the cost of cytostatic therapy of Korean traditional medicine is not covered by the
NHI. In spite of such high cost, patients still seek to traditional medicine of cyto-
static therapy. Characteristics of these patients and future research directions are
presented. METHODS: Cytostatic drug which is founded on Korean traditional
medicine is the main anti-cancer agents in our cancer center. Since this is oral
drug, oncology trained medical coordinators offered consultation including eligi-
bility for intake. After consultation eligible patients decide the first visit. We re-
viewed and analyzed telephone consultation logs and first visit medical records to
investigate patient characteristics. RESULTS: A total of 19,815 calls were received,
and about 25% made the first visit. Log showed similar gender, and wide range of
age. Most (67.7%) had one or more metastatic sites. Majority was able to eat and
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